180698-14-0

Basic information

• Product Name: 1-(3,5-difluorophenyl)piperazine
• Synonyms: 1-(3,5-difluorophenyl)piperazine
• CAS NO: 180698-14-0
• Molecular Formula: C₁₀H₁₂F₂N₂
• Molecular Weight: 198.21
• Mol File: 180698-14-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(3,5-difluorophenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,5-difluorophenyl)piperazine(180698-14-0)
• EPA Substance Registry System: 1-(3,5-difluorophenyl)piperazine(180698-14-0)

Safety Data

• Hazardous Substances Data: 180698-14-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(3,5-difluorophenyl)piperazine is used as a building block for the synthesis of pharmaceutical compounds, specifically for the development of central nervous system drugs. Its unique structure and properties make it a valuable component in creating new medications.
Used in Research and Development:
1-(3,5-difluorophenyl)piperazine is used as a subject of research in the development of new psychoactive substances. Its potential psychoactive properties have garnered interest in understanding its effects and applications in this field.
Used in Treatment of Neurological and Psychiatric Disorders:
1-(3,5-difluorophenyl)piperazine has been investigated for its potential use in the treatment of certain neurological and psychiatric disorders. Its involvement in the synthesis of drugs targeting the central nervous system makes it a promising candidate for further exploration and development in this area.

Upstream product

• 2265-91-0 1,3-difluoro-5-iodobenzene 
• 461-96-1 3,5-difluorobromobenzene 
• 909418-94-6 tert-butyl 4-(3,5-difluorophenyl)piperazine-1-carboxylate 
• 372-39-4 3,5-difluoroaniline 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 

Downstream Products

• 210992-25-9 1-[1-(3-Chloro-pyridin-2-yl)-5-methyl-4-pyrazolyl]-3-[4-(3,5-difluorophenyl)-1-piperazinyl]-1-propanone 
• 1553930-23-6 N-{2-[4-(3,5-difluorophenyl)piperazin-1-yl]ethyl}-2-quinoxalinecarboxamide 
• 1553930-16-7 N-{2-[4-(3,5-difluorophenyl)piperazin-1-yl]ethyl}-2-naphthalenecarboxamide 
• 1553930-02-1 N-{2-[4-(3,5-difluorophenyl)piperazin-1-yl]ethyl}phthalimide 
• 1027492-87-0 {2-amino-4-[(4-(3,5-difluorophenyl)piperazin-1-yl)methyl]thiophen-3-yl}(4-chlorophenyl)methanone 
• 1355155-99-5 2-{3-(4-chlorobenzoyl)-4-[(4-(3,5-difluorophenyl)piperazin-1-yl)methyl]thiophen-2-yl}-isoindole-1,3-dione 
• 201676-01-9 1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3,5-difluorophenyl)piperazine 
• 291510-99-1 1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)-piperazine 
• 291510-90-2 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)-piperazine 
• 291510-79-7 1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl) piperazine 
• 291510-57-1 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)-piperazine 

Relevant articles and documents

LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME

LpxH targeting compounds, compositions thereof, as well as methods for for making and using the same are disclosed herein. The LpxH target compounds typically have a structure pursuant to Formula (I) and/or a salt thereof, wherein Rb is selecte

Synthesis and evaluation of sulfonyl piperazine LpxH inhibitors

The UDP-2,3-diacylglucosamine pyrophosphate hydrolase LpxH is essential in lipid A biosynthesis and has emerged as a promising target for the development of novel antibiotics against multidrug-resistant Gram-negative pathogens. Recently, we reported the c

INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE

Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic disorders, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

PYRROLE mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

PYRROLE mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.

ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS

The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, n, X, Y and Z are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.

Parallel synthesis of N-arylpiperazines using polymer-assisted reactions

A series of N-arylpiperazines were prepared in a parallel fashion using palladium-catalyzed cross-coupling, or nucleophilic aromatic displacement chemistries, and polymer-assisted sequestration and purification techniques as key steps.

Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives. II. Optimization of the phenylpiperazine moiety of 1-[5-methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-3-phenylpiperazinyl-1-trans-propenes.

A series of novel 3-substituted-1-[5-methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-1-trans-propenes in order to improve the in vitro and in vivo activity of our prototype 3-[4-(3-chlorophenyl)-1-piperazinyl]-1-[5-methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-1-trans-propene (2) were synthesized and evaluated by assays of growth inhibition against several tumor cell lines in vitro and antitumor activity against some tumor models when dosed both intraperitoneally and orally in vivo. Compounds 7a and 7e, the 3,5-difluorophenyl and 3,5-dichlorophenyl analogues of 2, respectively, showed significantly more potent cytotoxicity than 2 in vitro and potent antitumor activities without causing decrease of body temperature related to side effects.